跳到正文
原文
MedPage Today·· 4 小时前精选AI 评分63

血液嗜酸性粒细胞水平可能预测最常见的乳腺癌复发风险

Simple Lab Test May Predict Recurrence Risk in Most Common Type of Breast Cancer

AI 导读

一项大型回顾性分析显示,血液嗜酸性粒细胞水平与HR阳性/HER2阴性乳腺癌患者的无复发生存率和无远处转移生存率显著相关。高嗜酸性粒细胞水平在多变量调整模型中仍然是独立的预后因素。该研究还发现,嗜酸性粒细胞水平预测了CDK4/6抑制剂的疗效。

推荐理由

研究发现血液中嗜酸性粒细胞水平与乳腺癌预后和CDK4/6抑制剂疗效相关,可作为预测生物标志物。

正文

— Higher eosinophil levels predicted better outcomes, better response to CDK4/6 inhibitors

November 19, 2026 • 4 min read

  • Higher circulating eosinophil levels predicted significantly better recurrence-free and distant metastasis-free survival in hormone receptor (HR)-positive/HER2-negative breast cancer.
  • Higher eosinophil counts identified HR-positive/HER2-negative breast cancer patients who derived greater benefit from CDK4/6 inhibitors.
  • Eosinophil counts added to prognostic information provided by existing methods.

Higher levels of circulating eosinophils had a significant association with improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in hormone receptor (HR)-positive breast cancer, a large retrospective analysis showed.

With an eosinophil cutoff of 0.08 × 109/L, patients with eosinophil counts above the cutoff had significantly better RFS (P=0.001) and DMFS (P=0.002). Higher levels of circulating eosinophils remained an independent predictor of improved outcomes in multivariable-adjusted statistical models. Reductions in the RFS and DMFS hazard ratios ranged between 50% and 60% before and after adjustment. The results were replicated in a large validation cohort of patients with HR-positive/HER2-negative breast cancer, albeit with smaller reductions in the hazard ratios.

Additionally, higher eosinophil counts predicted benefit from treatment with a CDK4/6 inhibitor, reported Zhi-Ming Shao, MD, PhD, of Fudan University Shanghai Cancer Center in China, and colleagues in the Journal of Clinical Oncology.

"Circulating eosinophil count is a robust prognostic biomarker, including during endocrine therapy," the authors stated. "Although the prognostic [hazard ratio] for eosinophil count differed between the discovery and expanded cohorts, this reflects differences in cohort design, case mix, and sample size; importantly, both estimates were directionally consistent, showing a protective effect."

"Second, [eosinophil count] provides significant additive prognostic value beyond the 21-gene risk score, suggesting that eosinophil levels in peripheral blood capture an immune dimension distinct from tumor genomics," they continued. "Third, eosinophils predict adjuvant CDK4/6 inhibitor efficacy, optimizing patient selection... . Importantly, the treatment-by-eosinophil interaction remained robust and the direction of effect was consistently protective across all analyses, supporting eosinophil count as a predictive biomarker regardless of absolute [hazard ratio] magnitude."

The findings add to previous studies showing that higher peripheral lymphocyte count and lower neutrophil-to-lymphocyte ratio are associated with better outcomes in early-stage breast cancer, primarily HR-negative subtypes, noted the authors of an accompanying editorial. Collectively, they highlight the biomarker potential of readily available laboratory parameters.

"None of these prognostic factors is in routine use, however, despite being readily available from a complete blood count for virtually every patient with breast cancer globally," wrote Peter Savas, MBBS, PhD, of Peter MacCallum Cancer Center in Melbourne, Australia, and Roberto Salgado, MD, PhD, of ZAS Hospitals in Antwerp, Belgium. "To achieve greater clinical relevance for circulating biomarkers, we can seek guidance from the success of risk-of-recurrence assays and the popularity of prognostic calculators such as PREDICT breast. These tools take a carefully considered approach to implementation, integrating standard clinicopathologic variables in a form that supports shared decision making and communication with patients."

"This should be the aim for any proposed biomarker that hopes to see widespread uptake, in addition to robust analytical and clinical validation."

Unmet Biomarker Need

HR-positive/HER2-negative breast cancer accounts for about two-thirds of all new cases of breast cancer, and despite treatment advances, late recurrence and distant relapse have persisted, the authors noted in their introduction. The absence of simple, noninvasive, blood-based biomarkers to monitor dynamic systemic immune status remains an unmet need. In particular, robust biomarkers to predict therapeutic benefit from CDK4/6 inhibitors have remained elusive, despite the drugs' established role in treating patients with HR-positive/HER2-negative breast cancer.

To date research into immune prognostic markers has focused primarily on tumor-infiltrating lymphocytes, ignoring the "prognostically relevant" myeloid compartment, the authors continued. To address the information void, investigators evaluated the prognostic potential of eosinophils, which previous studies have shown can prime antitumor T-cell responses. Investigators hypothesized that circulating eosinophil count could serve as a dynamic systemic marker of immune competence, distinct from tumor lymphoid infiltration.

Shao and colleagues retrospectively analyzed eosinophil counts in 472 patients with HR-positive/HER2-negative breast cancer treated with surgery and followed for a median of 83.1 months. The cohort had a median eosinophil count of 0.08 × 109/L. The cohort comprised 259 patients with eosinophil counts higher than the median and 213 with counts at the median or lower.

The data showed that patients with eosinophil counts exceeding the median had a 54% lower hazard for RFS (95% CI 0.28-0.77) and a 56% lower hazard for DMFS (95% CI 0.25-0.78). Multiple variable analyses produced hazard ratios of 0.49 (P=0.007) and 0.50 (P=0.017) for RFS and DMFS, respectively. Among 406 patients treated with endocrine therapy, higher eosinophil counts predicted better RFS (HR 0.41, 95% CI 0.24-0.70, P=0.001) and DMFS (HR 0.39, 95% CI 0.21-0.72, P=0.002).

Laboratory Evidence, Validation Cohort

To evaluate the functional impact of circulating eosinophil infiltration, the investigators implanted eosinophils into the mammary fat pads of mouse models of HR-positive/HER2-negative breast cancer. The results showed significantly reduced tumor growth in animals that received eosinophils versus those that did not.

Finally, Shao and colleagues investigated circulating eosinophils' association with RFS and DMFS in a validation cohort of 23,177 patients, 10,488 with eosinophil counts exceeding the median and 10,689 with values at or below the median. They had a median follow-up of 32.6 months. The high-eosinophil group had a statistically significant 17% lower risk of distant metastasis (95% CI 0.70-0.99, P=0.034). The association remained significant in a multivariable analysis that included age, nodal status, tumor size, and Ki67 value.

A separate analysis of 3,471 high-risk patients treated with adjuvant CDK4/6 inhibitors showed that the therapy improved DMFS overall, but patients with higher eosinophil counts derived greater benefit (HR 0.25, 95% CI 0.12-0.48, P<0.0001) than those with lower counts (HR 0.59, 95% CI 0.38-0.93, P=0.022).

来源:MedPage Today · medpagetoday.com